Recognition for outstanding results in Medicines Australia’s Continuing Education Program

19 March 2025: Medicines Australia congratulates the winners of last year’s Medicines Australia’s Continuing Education Program (CEP) Awards.

These annual Awards for individuals in the pharmaceutical and health sectors recognise outstanding results during the 2024 academic year of the Medicines Australia CEP.

There are three award categories:

  • The University of Tasmania (UTAS) Prize for Excellence Award – presented to one student per semester and only applies to programs that require submission of a written assignment.
  • The Code of Conduct Award – presented to one student who achieves the highest mark for Program 1: Medicines Australia Code of Conduct.
  • The CEP Award – presented to 10 students who achieve the 10 highest aggregate marks for five core programs.

CEO of Medicines Australia, Liz de Somer explained that the CEP is offered online through the UTAS and provides students with the confidence, skills and knowledge needed to ensure medical representatives meet recognised industry standards.

“Congratulations to all our award recipients on their outstanding achievements in 2024. Completing such an important course, and with such excellent results, is a testament of our award winners’ dedication and commitment to their profession,” Ms de Somer, CEO of Medicines Australia said.

Long-An Lam from Pfizer Australia was awarded the UTAS Active Learning Prize for Semester 1, and Tejal Chauhan from AstraZeneca was awarded the UTAS Prize for Excellence Semester 2, together with a CEP Achievement Award.

“The Medicines Australia CEP provided me with invaluable insights into opportunities to further improve our engagements with all stakeholders across the Australian medicines sector. The understanding and context gained from the program promoted discussion and positive actions in working collaboratively to ensure the quality use of medicines in Australia,” Long-An Lam said on receiving the UTAS Active Learning Prize.

Tejal Chauhan said, “the Medicines Australia CEP has been instrumental in building my confidence and enhancing my ability to navigate industry regulations and ethical promotion. It has deepened my understanding of supporting healthcare professionals and patient outcomes with integrity. I’m grateful for the learning experience and the recognition of my commitment to continuous professional development.”

This year’s recipient of the Code of Conduct Award was Cathrynn Badenhorst from Novo Nordisk. “I was delighted to receive the Code of Conduct Achievement Award for Program 1. This course provided a thorough grounding in Medicines Australia Code of Conduct requirements and insights and was presented in a very practical and interactive way. Together with daily lived experience and support from amazing colleagues, the CEP has allowed me to adapt to the pharmaceutical industry very quickly,” Cathrynn Badenhorst said.

Ms de Somer said, “Thank you Medicines Australia member companies for investing in your teams by supporting this essential training and I congratulate everyone who has successfully completed the CEP over the past year.”

Full list of winners

  • Long-An Lam (Pfizer Australia) – UTAS Prize for Excellence Semester 1
  • Tejal Chauhan (AstraZeneca) – UTAS Prize for Excellence Semester 2 and CEP Achievement Award
  • Cathryn Badenhorst (Novo Nordisk) – Code of Conduct Achievement Award
  • Peter Lwin (previously GSK) – CEP Achievement Award
  • Victoria Cullen (previously GSK) – CEP Achievement Award
  • Joel Mannix (BeiGene) CEP Achievement Award
  • Yvonne Brown (Otsuka Australia) – CEP Achievement Award
  • Georgia Taylor (Pfizer Australia) – CEP Achievement Award
  • Navi Deol (GSK Australia) – CEP Achievement Award
  • Jamie Fowler (Servier Laboratories) – CEP Achievement Award
  • Sean Sheppard (Boehringer Ingelheim) – CEP Achievement Award
  • Miral Georgy (GSK Australia) – CEP Achievement Award

About the Continuing Education Program (CEP)

Medicines Australia’s Continuing Education Program (CEP) was launched in 1996 and is designed to educate medical representatives working within the prescription medicines industry, to a recognised industry standard.

The program is delivered by our education partner, University of Tasmania. Completion of the CEP is mandatory all medical representatives entering the Australian prescription pharmaceutical industry for the first time.

These courses are also recommended to people who may not be currently employed within the industry but would like to pursue a career as a medical representative.

Courses available include the Medicines Australia Code of Conduct, The Pharmaceutical and Healthcare Industry, Human Anatomy and Physiology, an Introduction to Pharmacology, Product Information, Understanding Product Information, and Understanding Clinical Evidence.

More information is available on Medicines Australia’s website here.

_______________________________________________________________________

Media enquiries to: Anne-Marie Sparrow, Medicines Australia /Cube – media@medicinesaustralia.com.au or 0417 421 560